These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 35406787)
1. Johnson SL; Prifti MV; Sujkowski A; Libohova K; Blount JR; Hong L; Tsou WL; Todi SV Cells; 2022 Apr; 11(7):. PubMed ID: 35406787 [TBL] [Abstract][Full Text] [Related]
2. RAN Translation of the Expanded CAG Repeats in the SCA3 Disease Context. Jazurek-Ciesiolka M; Ciesiolka A; Komur AA; Urbanek-Trzeciak MO; Krzyzosiak WJ; Fiszer A J Mol Biol; 2020 Dec; 432(24):166699. PubMed ID: 33157084 [TBL] [Abstract][Full Text] [Related]
3. Preimplantation Genetic Testing of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease-Robust Tools for Direct and Indirect Detection of the Lian M; Tan VJ; Taguchi R; Zhao M; Phang GP; Tan AS; Liu S; Lee CG; Chong SS Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125643 [TBL] [Abstract][Full Text] [Related]
4. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629 [TBL] [Abstract][Full Text] [Related]
5. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
6. Expanded ATXN3 frameshifting events are toxic in Drosophila and mammalian neuron models. Stochmanski SJ; Therrien M; Laganière J; Rochefort D; Laurent S; Karemera L; Gaudet R; Vyboh K; Van Meyel DJ; Di Cristo G; Dion PA; Gaspar C; Rouleau GA Hum Mol Genet; 2012 May; 21(10):2211-8. PubMed ID: 22337953 [TBL] [Abstract][Full Text] [Related]
7. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3. Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633 [TBL] [Abstract][Full Text] [Related]
8. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119 [TBL] [Abstract][Full Text] [Related]
9. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
10. Population genetics and new insight into range of CAG repeats of spinocerebellar ataxia type 3 in the Han Chinese population. Gan SR; Ni W; Dong Y; Wang N; Wu ZY PLoS One; 2015; 10(8):e0134405. PubMed ID: 26266536 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells. Ouyang S; Xie Y; Xiong Z; Yang Y; Xian Y; Ou Z; Song B; Chen Y; Xie Y; Li H; Sun X Stem Cells Dev; 2018 Jun; 27(11):756-770. PubMed ID: 29661116 [TBL] [Abstract][Full Text] [Related]
12. Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence. McGurk L; Rifai OM; Shcherbakova O; Perlegos AE; Byrns CN; Carranza FR; Zhou HW; Kim HJ; Zhu Y; Bonini NM Hum Mol Genet; 2021 Sep; 30(19):1797-1810. PubMed ID: 34077532 [TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of SCA3 and implications for other polyglutamine diseases. McLoughlin HS; Moore LR; Paulson HL Neurobiol Dis; 2020 Feb; 134():104635. PubMed ID: 31669734 [TBL] [Abstract][Full Text] [Related]
14. PolyQ-independent toxicity associated with novel translational products from CAG repeat expansions. Rudich P; Watkins S; Lamitina T PLoS One; 2020; 15(4):e0227464. PubMed ID: 32240172 [TBL] [Abstract][Full Text] [Related]
16. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression. Shi Y; Wang C; Huang F; Chen Z; Sun Z; Wang J; Tang B; Ashizawa T; Klockgether T; Jiang H Cerebellum; 2015 Dec; 14(6):677-81. PubMed ID: 25869927 [TBL] [Abstract][Full Text] [Related]
17. Variants in Genes of Calpain System as Modifiers of Spinocerebellar Ataxia Type 3 Phenotype. Martins AC; Rieck M; Leotti VB; Saraiva-Pereira ML; Jardim LB J Mol Neurosci; 2021 Sep; 71(9):1906-1913. PubMed ID: 34191270 [TBL] [Abstract][Full Text] [Related]
18. Selective forces acting on spinocerebellar ataxia type 3/Machado-Joseph disease recurrency: A systematic review and meta-analysis. Sena LS; Dos Santos Pinheiro J; Saraiva-Pereira ML; Jardim LB Clin Genet; 2021 Mar; 99(3):347-358. PubMed ID: 33219521 [TBL] [Abstract][Full Text] [Related]
19. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Ranum LP; Lundgren JK; Schut LJ; Ahrens MJ; Perlman S; Aita J; Bird TD; Gomez C; Orr HT Am J Hum Genet; 1995 Sep; 57(3):603-8. PubMed ID: 7668288 [TBL] [Abstract][Full Text] [Related]
20. Lysine 117 on ataxin-3 modulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Blount JR; Patel NC; Libohova K; Harris AL; Tsou WL; Sujkowski A; Todi SV J Neurol Sci; 2023 Nov; 454():120828. PubMed ID: 37865002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]